<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05627843</url>
  </required_header>
  <id_info>
    <org_study_id>MD 181 / 2021</org_study_id>
    <nct_id>NCT05627843</nct_id>
  </id_info>
  <brief_title>Effects of Curcumin on Inflammation and Oxidative Stress in Pediatric Patients on Regular Hemodialysis: A Randomized, Double-Blind, Placebo-Controlled Pilot Study</brief_title>
  <official_title>Effects of Curcumin on Inflammation and Oxidative Stress in Paediatric Patients on Regular Hemodialysis: A Randomized, Double-Blind, Placebo-Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The study will be a randomised, double blinded, placebo controlled design.&#xD;
&#xD;
        -  It will include 2 groups : trial group and placebo group&#xD;
&#xD;
        -  Patients in both groups are children on regular hemodialysis&#xD;
&#xD;
        -  The patients in the trial group will receive Curcumin capsule 1 gm for 3 months , and&#xD;
           the placebo group will receive a placebo capsule for 3 months&#xD;
&#xD;
        -  All patients will be evaluated clinically, and laboratory at baseline, at 3 months after&#xD;
           end of supplementation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2022</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>inflammatory marker</measure>
    <time_frame>3 months</time_frame>
    <description>high sensitivity C reactive protein (CRP) at baseline before supplementation and after 3 months of supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress markers</measure>
    <time_frame>3 months</time_frame>
    <description>Serum tumor necrotizing factor alpha (TNF alpha)and malondialdehyde (MDA)at baseline and after 3 months of supplementation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pediatric Patients Having Renal Failure and on Regular Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Trial group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children on regular hemodialysis whose weight 30 kg or above</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Children on regular hemodialysis whose weight 30 kg or above</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curcumin capsules 1 gm</intervention_name>
    <description>Dietary supplement</description>
    <arm_group_label>Trial group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>placebo corn starch</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female pediatric patients with weight of at least 30 kilograms.&#xD;
&#xD;
          -  Undergoing regular hemodialysis for at least 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bleeding disorders.&#xD;
&#xD;
          -  Chronic liver disease.&#xD;
&#xD;
          -  Diabetes mellitus.&#xD;
&#xD;
          -  Autoimmune diseases.&#xD;
&#xD;
          -  Receiving drugs that are contraindicated, or have major interactions with curcumin,&#xD;
             and can't be discontinued or replaced.&#xD;
&#xD;
          -  Receiving corticosteroids, or immune-suppressants.&#xD;
&#xD;
          -  Patients taking any antioxidant supplements including vitamin E, ascorbic acid, omega&#xD;
             -3 fatty acid, or L-carnitine within 3 months prior to enrollment in our study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Iman Alagamy, Master degree in pediatrics</last_name>
    <phone>01201724974</phone>
    <email>Iman.agamy@live.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Iman Mohamed Naguib Alagamy</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iman Alagamy</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 23, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2022</study_first_posted>
  <last_update_submitted>November 23, 2022</last_update_submitted>
  <last_update_submitted_qc>November 23, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Iman Mohamed Naguib Alagamy</investigator_full_name>
    <investigator_title>Assistant lecturer at Misr university for science and technology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

